Atara Biotherapeutics, Inc.ATRANASDAQ
Loading
Year-over-year net income growth rate
3Y CAGR
+22.6%/yr
vs +46.5%/yr prior
Acceleration
-23.9pp
Decelerating
Percentile
P79
Within normal range
vs 3Y Ago
1.8x
Solid growth
Streak
1 qtr
Consecutive growthAccelerating
| Period | Value |
|---|---|
| Q4 2025 | 20.85% |
| Q3 2025 | -280.27% |
| Q2 2025 | -93.72% |
| Q1 2025 | 399.46% |
| Q4 2024 | 42.06% |
| Q3 2024 | -15.01% |
| Q2 2024 | 40.01% |
| Q1 2024 | 47.47% |
| Q4 2023 | 13.39% |
| Q3 2023 | 1.84% |
| Q2 2023 | 4.90% |
| Q1 2023 | -0.27% |
| Q4 2022 | 11.32% |
| Q3 2022 | -555.38% |
| Q2 2022 | 120.96% |
| Q1 2022 | 5.62% |
| Q4 2021 | -10.26% |
| Q3 2021 | -1.04% |
| Q2 2021 | -6.97% |
| Q1 2021 | 3.66% |
| Q4 2020 | -9.36% |
| Q3 2020 | 4.01% |
| Q2 2020 | -5.37% |
| Q1 2020 | 6.35% |
| Q4 2019 | 89.08% |
| Q3 2019 | 3.27% |
| Q2 2019 | -12.18% |
| Q1 2019 | 17.19% |
| Q4 2018 | -37.10% |
| Q3 2018 | -14.70% |
| Q2 2018 | -22.78% |
| Q1 2018 | -17.36% |
| Q4 2017 | -13.56% |
| Q3 2017 | -13.37% |
| Q2 2017 | -6.92% |
| Q1 2017 | -40.69% |
| Q4 2016 | 28.13% |
| Q3 2016 | -34.39% |
| Q2 2016 | -14.00% |
| Q1 2016 | 22.06% |